EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

Hongmeng Zhao, Dan Li, Qian Li, Bin Zhang, Chunhua Xiao, Ying Zhao, Jie Ge, Yue Yu, Yumian Jia, Xiaojing Guo, Xuchen Cao, Xin Wang iD

The Oncologist · 03.06.2024 · 29 (6) · e763-e770

DOI: 10.1093/oncolo/oyae033 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift The Oncologist, online erschienen am 09.03.2024. Verfasst von Hongmeng Zhao und 11 weiteren Autor:innen. Beteiligte Einrichtung: The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianji…. Hauptthemen laut MEDLINE: Breast Neoplasms, Androstadienes, Erb-b2 Receptor Tyrosine Kinases, Neoadjuvant Therapy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tianin Key Medical Discipline, National Natural Scientific Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To assess the efficacy and safety of tucidinostat plus exemestane as a neoadjuvant strategy in early-stage breast cancer.

Methods

This prospective, open-label, single-arm phase II trial enrolled patients with stage II-III breast cancer with hormone receptor-positive and human epidermal growth factor receptor 2 (HER2)-negative. Eligible patients received tucidinostat plus exemestane, and then breast-conserving surgery (BCS) or modified radical mastectomy.

Results

Among 20 enrolled patients, 3 of them achieved preoperative endocrine prognostic index (PEPI) score of 0. Additionally, complete cell cycle arrest was observed in 7, radiologic objective response rate in 10, and disease control rate in 20 patients, pathological complete response in 1 patient, and 5 patients performed BCS. Ki67 suppression from baseline to surgery was observed in 17 of patients, with the Ki67 change ratio of −73.5%. Treatment-emergent adverse event included neutropenia, leukopenia, thrombocytopenia, lymphopenia, hypoalbuminemia, aspartate aminotransferase elevation, glutamyl transpeptidase elevation, anemia, and alanine aminotransferase elevation.

Conclusions

Despite the rate of PEPI score 0 was not high, tucidinostat plus exemestane as a neoadjuvant therapy might be well tolerated and showed promising clinical responses in patients with early hormone receptor-positive, HER2-negative breast cancer. To clarify the safety and efficacy of this strategy, further investigation is warranted. Clinical Trial Registration ChiCTR2100046678.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsAndrostadienesErb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleMiddle AgedAdultAgedReceptors, EstrogenProspective StudiesReceptors, ProgesteroneNeoplasm Staging

Stichwörter der Autor:innen

Ki67hormone receptor-positiveneoadjuvant treatmenttucidinostat

Substanzen

AndrostadienesErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenReceptors, ProgesteroneexemestaneERBB2 protein, human

Autor:innen und Institutionen

  • The First Department of Breast Cancer, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300060, People's Republic of China.
  • The Department of Breast Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin 300060, People's Republic of China.

ORCID-Profile: Xin Wang

Förderung

  • Tianin Key Medical Discipline
  • National Natural Scientific Foundation of China

Zitieren

APA

Zhao, H., Li, D., Li, Q., Zhang, B., Xiao, C., Zhao, Y., Ge, J., Yu, Y., Jia, Y., Guo, X., Cao, X., & Wang, X. (2024). Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. The Oncologist, 29(6), e763-e770. https://doi.org/10.1093/oncolo/oyae033

Vancouver

Zhao H, Li D, Li Q, Zhang B, Xiao C, Zhao Y, et al. Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. The Oncologist. 2024;29(6):e763-e770. doi:10.1093/oncolo/oyae033

BibTeX
@article{Zhao2024,
  author = {Zhao, Hongmeng and Li, Dan and Li, Qian and Zhang, Bin and Xiao, Chunhua and Zhao, Ying and Ge, Jie and Yu, Yue and Jia, Yumian and Guo, Xiaojing and Cao, Xuchen and Wang, Xin},
  title = {Tucidinostat Plus Exemestane as a Neoadjuvant in Early-Stage, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer},
  journal = {The Oncologist},
  year = {2024},
  volume = {29},
  number = {6},
  pages = {e763--e770},
  doi = {10.1093/oncolo/oyae033}
}
Kostenlos starten →